Insight Molecular Diagnostics Inc.

IMDX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Assets
Cash & Equivalents $11.6M $8.6M $9.4M $20.0M $32.9M $7.1M $22.1M $8.0M
Accounts Receivable $1.1M $1.6M $484.0K $2.0M $1.4M $203.0K
Inventory $446.0K $410.0K
Total Current Assets $15.3M $11.8M $10.7M $25.5M $39.1M $9.2M $23.0M $8.6M
Property, Plant & Equipment $9.3M $6.3M $4.7M $8.7M $7.1M $4.4M $3.6M $614.0K
Goodwill $18.7M $9.2M
Intangible Assets (Excl. Goodwill) $0 $14.6M $56.6M $61.6M $61.7M $15.0M
Total Assets $25.8M $35.1M $74.9M $100.1M $159.6M $55.4M $39.9M $9.5M
Liabilities
Accounts Payable $2.5M $1.6M $953.0K $1.3M $1.8M $432.0K $469.0K $166.0K
Total Current Liabilities $12.1M $7.3M $7.2M $12.1M $14.1M $9.0M $4.4M $5.6M
Long-Term Debt
Total Liabilities $57.2M $47.4M $49.3M $60.5M $94.3M $21.9M $9.0M $6.1M
Stockholders' Equity
Retained Earnings $-400.8M $-350.5M $-289.9M $-260.7M $-187.8M $-123.7M $-93.7M $-71.3M
Total Stockholders' Equity $-31.5M $-12.3M $20.5M $34.3M $65.2M $33.5M $30.8M $3.4M
← Newer Page 1 of 2 Older →